You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
|
---|---|
Published in |
Journal of Hematology & Oncology, March 2014
|
DOI | 10.1186/1756-8722-7-24 |
Pubmed ID | |
Authors |
Nancy L Bartlett, Robert Chen, Michelle A Fanale, Pauline Brice, Ajay Gopal, Scott E Smith, Ranjana Advani, Jeffrey V Matous, Radhakrishnan Ramchandren, Joseph D Rosenblatt, Dirk Huebner, Pamela Levine, Laurie Grove, Andres Forero-Torres |
Abstract |
Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (ALCL) who relapsed after achieving complete or partial remission (CR or PR) with initial brentuximab vedotin therapy in a previous study (ClinicalTrials.gov NCT00947856). |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 20% |
Russia | 1 | 20% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Japan | 1 | <1% |
India | 1 | <1% |
Peru | 1 | <1% |
Unknown | 110 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 28 | 25% |
Other | 21 | 18% |
Student > Master | 9 | 8% |
Professor | 7 | 6% |
Student > Bachelor | 6 | 5% |
Other | 20 | 18% |
Unknown | 23 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 52 | 46% |
Biochemistry, Genetics and Molecular Biology | 6 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
Nursing and Health Professions | 5 | 4% |
Agricultural and Biological Sciences | 4 | 4% |
Other | 15 | 13% |
Unknown | 26 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#4,130,047
of 25,380,089 outputs
Outputs from Journal of Hematology & Oncology
#354
of 1,291 outputs
Outputs of similar age
#38,753
of 236,492 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 17 outputs
Altmetric has tracked 25,380,089 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,291 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 236,492 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.